US 12,649,029 B2Granted

Optimized bio-synchronous bioactive agent delivery system

AssigneeMorningside Venture Investments Limited

InventorsGuy DiPierro, Alan Joel Levy

Life of this patent

Estimating the term…

Loading patent…

Abstract

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

Claims15

Dependent claims

A method for using a trans-dermal bioactive agent delivery device for optimizing bio-synchronous drug delivery, the method comprising:

establishing a bio-synchronous treatment protocol comprising bioactive agent delivery and temporal psychological support;
initiating the bio-synchronous treatment protocol wherein the bio-synchronous treatment protocol includes use of a bio-synchronous bioactive agent delivery device;
gathering patient data during the bio-synchronous treatment protocol;
analyzing patient data gathered by the trans-dermal bioactive agent delivery device;
determining based on gathered patient data whether modification to the bio-synchronous treatment protocol is required;
and
responsive to determining whether modification to the bio-synchronous treatment protocol is required, modifying the bio-synchronous treatment protocol to a modified bio-synchronous treatment protocol;
and
using the trans-dermal bioactive agent delivery device to administer the modified bio-synchronous treatment protocol.

6 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/936,750Filed 29 Sep 2022 · continuation
Priority: 24 Jan 2013
Published: US 2023/0277767 A17 Sep 2023
Granted: 9 Jun 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61M 5/1723
Electrical or electronic: using feedback of body parameters, e.g. blood sugar or pressure
A61M 5/30
Syringes: syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
A61P 1/08
Drugs for disorders of the alimentary tract or the digestive system: for nausea, cinetosis or vertigo; Antiemetics
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents

Family

Application61/756,339Us provisional application · filed 24 Jan 2013
Application14/156,998Parent of this division · filed 16 Jan 2014
Application16/165,720Parent of this continuation · filed 19 Oct 2018
US 10,105,487 B2Parent of this division · filed 23 Oct 2018
US 2023/0277767 A1Pre-grant publication · published 7 Sep 2023
Application16/165,720Parent of this division
US 2014/0207048 A1Published application
US 2019/0054235 A1Published application
US 12,649,029 B2This patent

From the US filing history. Foreign family members aren’t listed.